智飞生物：吸附无细胞百白破（组分）联合疫苗（成人及青少年用） 临床试验申请获受理

Core Viewpoint - The announcement indicates that Zhifei Biological's subsidiary has received approval for clinical trials of a new acellular DTP vaccine for adults and adolescents, filling a gap in the market for this demographic in China [1] Group 1: Company Developments - Zhifei Biological's wholly-owned subsidiary, Beijing Zhifei Green Bamboo Biological Pharmaceutical Co., Ltd., has developed an acellular DTP (Diphtheria, Tetanus, Pertussis) combined vaccine [1] - The vaccine is intended for healthy individuals aged 7 and above to prevent whooping cough, diphtheria, and tetanus [1] - The National Medical Products Administration has accepted the drug clinical trial application, allowing clinical trials to commence if no objections are raised within 60 days [1] Group 2: Market Context - Currently, there are no approved acellular DTP vaccines available for adolescents and adults in the domestic market [1]